ClinicalTrials.gg
CompletedNCT06144840INSPIREUpdated Jun 4, 2026

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP

A Phase 3 interventional study of Dersimelagon and Placebo in Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP), sponsored by Tanabe Pharma America, Inc.. Completed at 35 sites in 11 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Tanabe Pharma America, Inc. (part of Tanabe Pharma Corporation) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Protoporphyria, Erythropoietic with a site in United States — 4 open to participants now, 4 under way, 2 of them phase 3. Protoporphyria, Erythropoietic · United States.

Enrollment
4th of 13
165 · median 77
Started
2023
with 1 other
Phase 3
3 of 18
none open now
Registered
13th of 18
by date
Lead sponsor
2 of 18
Tanabe Pharma America, Inc.

Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 in phase 3, and was the 13th registered.

Protoporphyria, Erythropoietic

29 studies on the registry are indexed under Protoporphyria, Erythropoietic; 5 are open to participants now.

Browse Protoporphyria, Erythropoietic studies →

Open to participants now

4 of the 18 studies in Protoporphyria, Erythropoietic with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Protoporphyria, Erythropoietic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Protoporphyria, Erythropoietic with a site in United States, or all of them as a file.
02

Study summary

To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.

03

Conditions studied

  • Erythropoietic Protoporphyria (EPP)
  • X-Linked Protoporphyria (XLP)
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects provided written to participate. For minor subjects, both minor's assent and parental consent will be required.
  2. Male and female subjects with a confirmed diagnosis of EPP or XLP based on medical history.
  3. Subjects aged 12 years to 75 years, inclusive, at Screening.
  4. Subjects are willing and able to travel to the study sites for all scheduled visits.
  5. In the Investigator's opinion, subject can understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements (including travel and receiving direct sunlight exposure as much as possible).
  6. Female subjects who are non-lactating and have a negative urine pregnancy test at baseline visit prior to receiving the first dose of study drug.
  7. Female subjects of and male subjects with partner of child-bearing potential currently using/willing to use 2 effective methods of .

Additional screening criteria check may apply for qualification.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of photodermatoses other than EPP or XLP.
  2. Subjects who are unwilling or unable to go outside in sunlight during daylight hours most days (e.g., between 1-hour post-sunrise and 1 hour pre-sunset) during the study.
  3. Presence or history of any hepatobiliary disease, including druginduced liver injury at screening, determined as by the Investigator after the discussion with the Sponsor Medical Monitor.
  4. Subjects with (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) ≥ 2.0 × (ULN) or total >1.5 × ULN at Screening.
  5. History (in the last 2 years) or presence of alcohol abuse, or abuse of illicit drugs in the opinion of the Investigator.
  6. History of melanoma.
  7. Presence of squamous cell carcinoma, basal cell carcinoma, or other malignant skin lesions. Any suspicious lesions or nevi will be evaluated. If the suspicious lesion or nevi cannot be resolved through or excision, the subject will be excluded from the study.
  8. History or presence of psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation and/or safety of the subjects.
  9. Presence of clinically significant acute or chronic renal disease or subjects with an estimated (eGFR) \<60 mL/min as calculated by the Chronic Kidney DiseaseEpidemiology Collaboration (CKD-EPI) creatinine equation (2021) for adults and by the Schwartz creatinine equation for adolescents (2009). Modification of Diet in Renal Disease can be used for adults per local recommendations.
  10. Presence of any clinically significant disease or laboratory abnormality which, in the opinion of the Investigator, can interfere with the study objectives and/or safety of the subjects.
  11. Female subjects who are pregnant, lactating, or intending to become pregnant during the study.
  12. Treatment with any of the following medications or therapy within each period before Randomization (Visit 2);

    • Afamelanotide within 3 months
    • Phototherapy within 3 months
    • Cimetidine within 4 weeks
    • Antioxidant agents within 4 weeks, at doses which, in the opinion of the Investigator, may affect study endpoints (including but not limited to beta-carotene, cysteine, pyridoxine).
    • Chronic treatment with any scheduled analgesic agents including, but not limited to, opioids and opioid derivatives such as morphine, hydrocodone, oxycodone, fentanyl, or their combination with other unscheduled analgesics or non-steroidal anti-inflammatory drug (Percocet and Vicodin-like prescription drugs) within 4 weeks.

    Note: Acute use of scheduled narcotics more than 3 months prior to randomization are allowed. Non-steroidal anti-inflammatory drug, aspirin for analgesia, or prior temporary use of scheduled agents within 3 months of screening is allowed.

  13. Dermatological treatments with any drugs or supplements which, in the opinion of the Investigator, can interfere with the objectives of the study or safety of the subjects at screening, such as, for example, tanning agents.
  14. Subjects who participated in any previous MT-7117 clinical studies.
  15. Previous treatment with any agent such as bitopertin, within 12 weeks before Screening or 5 half-lives of the investigational product (whichever is longer).
  16. Use of sunscreens with zinc oxide. Note: Sunscreens without zinc oxide are allowed, however their use, in frequency, quantity and body surface area should be maintained relatively stable throughout the duration of the study.
  17. History of any to the active ingredient and/or (lactose monohydrate, hydroxypropylcellulose, carmellose calcium, magnesium stearate, hypromellose, titanium dioxide, talc, polyethylene glycol, iron oxide yellow, iron oxide red, and iron oxide black). (EU ONLY)
  18. Subjects who are unable to swallow tablets or have diseases significantly affecting the gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.(EU ONLY)
  19. History of any hypersensitivity to the active ingredient and/or excipients contained in MT-7117 IMP (lactose monohydrate, hydroxypropyl cellulose, carmellose calcium, magnesium stearate, hypromellose, titanium dioxide, talc, polyethylene glycol, iron oxide yellow, iron oxide red, and iron oxide black). (UK ONLY)

Additional screening criteria check may apply for qualification.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    MT-7117

    Drug: Dersimelagon

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in average daily sunlight exposure time (minutes) to first prodromal symptom (burning, tingling, itching, or stinging) associated with sunlight exposure between 1 hour post-sunrise and 1 hour pre-sunset at Week 16

    The comparison between MT-7117 treatment group and placebo group will be performed.

    Time frame: Week 16

Secondary outcomes

  1. Patient Global Impression of Change (PGIC) at Week 16.

    The comparison between MT-7117 treatment group and placebo group will be performed.

    Time frame: Week 16

  2. Total number of sunlight-induced pain events defined as prodromal symptoms (burning, tingling, itching, or stinging) with pain rating of 1-10 on the Likert scale during the 16-week double-blind treatment period.

    The comparison between MT-7117 treatment group and placebo group will be performed.

    Time frame: Week 16

  3. Total number of sunlight-induced non-prodrome, phototoxic reactions during the 16-week double-blind treatment period.

    The comparison between MT-7117 treatment group and placebo group will be performed.

    Time frame: Week 16

07

Study locations

35 sites
  • Marvel Clinical Research, LLC
    Huntington Beach, California 92647, United States
  • University of California at San Francisco
    San Francisco, California 94143, United States
  • University Of Miami School Of Medicine, Center For Liver Diseases
    Miami, Florida 33136, United States
  • MGH
    Boston, Massachusetts 02129, United States
  • MetroBoston Clinical Partners, LLC
    Brighton, Massachusetts 02135-3511, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)
    New York, New York 10029-0311, United States
  • Wake Forest University Baptist Health
    Winston-Salem, North Carolina 27103, United States
  • Remington-Davis Clinical Research
    Columbus, Ohio 43215, United States
  • Einstein Medical Center (EMC)
    Philadelphia, Pennsylvania 19141, United States
  • The University of Texas Medical Branch (UTMB)
    Galveston, Texas 77555-0342, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • Royal Melbourne Hospital (RMH)
    Parkville, Victoria 03050, Australia
  • University Multi-Profile Hospital for Active Treatment (UMHAT) St. Ivan Rilski - Porphyria Center
    Sofia, 01000, Bulgaria
  • Institute for Clinical and Experimental Medicine - IKEM
    Prague, 01958, Czechia
  • Centre Hospitalier Universitaire de Bordeaux - Hopital Saint - Andre
    Bordeaux, 33000, France
  • CHU Nantes
    Nantes, 44000, France
  • Hôpital Bichat - Hospital Bichat-Hopitaux Universitaires Paris Nord Val de Seine
    Paris, 75018, France
  • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Louis-Mourier
    Paris, 92701, France
  • Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia
    Brescia, 25123, Italy
  • Azienda Sanitaria Ospedaliera Santa Croce E Carle - Cuneo
    Cuneo, 12100, Italy
  • Ospedalle Galliera
    Genova, 16128, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano
    Milan, 20122, Italy
  • U.O.C. Medicina Interna Azienda ospedaliero Universitaria Policlinico di Modena
    Modena, 41124, Italy
  • IFO-San Gallicano IRCCS
    Rome, 00144, Italy
  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Materno-Infantile - Burlo Garofolo - Clinica Pediatrica
    Trieste, 34137, Italy
  • Mazda Hospital
    Aki-gun, Hiroshima 735-8585, Japan
  • Hamamatsu University Hospital
    Hamamatsu, Shizuoka 431-3194, Japan
  • Tokyo Saiseikai Central Hospital
    Tokyo, 108-0073, Japan
  • Universitair Medisch Centrum Rotterdam
    Rotterdam, 03015, Netherlands
  • Instytut Hematologii I Transfuzjologii
    Warsaw, 02-776, Poland
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital General Universitario De Valencia
    Valencia, 46014, Spain
  • Guy's Hospital
    London, SE1 9RT, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Apr 2026, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2023
First posted
Nov 22, 2023
StartActual
Dec 11, 2023
Primary completionActual
Apr 14, 2026
CompletionActual
May 19, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06144840
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Dec 11, 2023
Primary completion
Apr 14, 2026
Completion
May 19, 2026
Last update
Jun 4, 2026

Study contacts

Head of Medical Science
study director · Tanabe Pharma America, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dersimelagon

Start the discussion